Vandria’s VNA-318 enters clinical trials for treating age-related diseases
Vandria - 18-Dec-2024Early tests have shown VNA-318 could improve brain function and reduce brain cell damage
Join the club for FREE to access the whole archive and other member benefits.
Early tests have shown VNA-318 could improve brain function and reduce brain cell damage
Long-term follow-up data and post-hoc analyses fuel optimism for treating mitochondrial diseases
Phase 2 trial on sonlicromanol to test its ability in improving patient's symptoms & quality of life
Chronic inflammation and fibrosis further damage the heart health
New research from Texas A&M develops nanoflowers to restore cellular energy
Click on resource name for more details.
Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell
Biopharmaceutical company focused on the discovery and commercialization of novel therapies..
Reactive oxygen species (ROS) have a positive role in some processes, complicating research, but unlikely that antioxidants slow ageing
Review paper from University of Helsinki looks at the role of mitophagy in ageing